RESISTANCE OF CANDIDA-ALBICANS TO FLUCONAZOLE DURING TREATMENT OF OROPHARYNGEAL CANDIDIASIS IN A PATIENT WITH AIDS - DOCUMENTATION BY IN-VITRO SUSCEPTIBILITY TESTING AND DNA SUBTYPE ANALYSIS
S. Redding et al., RESISTANCE OF CANDIDA-ALBICANS TO FLUCONAZOLE DURING TREATMENT OF OROPHARYNGEAL CANDIDIASIS IN A PATIENT WITH AIDS - DOCUMENTATION BY IN-VITRO SUSCEPTIBILITY TESTING AND DNA SUBTYPE ANALYSIS, Clinical infectious diseases, 18(2), 1994, pp. 240-242
We describe a patient with recurrent episodes of oropharyngeal candidi
asis who required progressively higher doses of fluconazole to control
the infection. The patient was treated for 14 infections over a 2-yea
r period with doses of fluconazole that ranged from 100 to 800 mg per
day. Clinical response, two methods of in vitro susceptibility testing
, and molecular epidemiologic techniques were evaluated for 12 of the
14 episodes. Ultimately, the patient became unresponsive clinically to
a dose of 800 mg of fluconazole per day. In vitro susceptibility test
ing of isolates obtained during these successive episodes of infection
revealed the development of resistance to fluconazole, and molecular
epidemiologic techniques confirmed the persistence of the same Candida
albicans strain throughout all 12 episodes.